Corporate strategies and tactics for more effective drug development.
February 25, 2013
By:
Kenneth Getz
Kenneth Getz of the Tufts Center for the Study of Drug Development looks at leveraging pharmacists as a channel to raise clinical research literacy among patient communities.
|
September 1, 2012
By:
Roy F. Waldron
There is much talk today about "open innovation" in business and research forums—but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector? Does it signal a change in the way pharmaceutical companies approach research and innovation?
|
June 1, 2012
By:
Ben Comer
As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory.
|
May 1, 2012
Companies know they need regulatory information management. What they don't always know is where to start and how to weave this vital capability across the enterprise.
|
|
November 1, 2011
Industry critics point to a lag in NME approvals as proof of innovation stagnation, but combination products and new delivery systems are quietly saving lives, and bringing in big dollars.
|
September 1, 2011
By:
William Looney
Pharm Exec talks to Dr. Mel Spigelman, President and CEO of the TB Alliance, about the organization's tuberculosis priorities.
|
September 1, 2011
By:
Richard Gilkich
Observational studies present a compelling real-world corollary to the classic randomized clinical trial.
|
|
September 1, 2011
Richard Barker, former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.
|
September 1, 2011
By:
Dr. Jill Conner
Industry and regulators alike must graple with the sensitivities associated with developing biosimilar drugs.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
